Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.87 |
| ▸ | NPC1 | O15118 | 6/20 | 0.87 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.87 |
| ▸ | ESRRG | P62508 | 2/20 | 0.79 |
| ▸ | MAPT | P10636 | 6/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | PKM | P14618 | 2/20 | 0.77 |
| ▸ | MEN1 | O00255 | 4/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.69 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.69 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL711754 | 0.96 | RAB9A (0.81) | RAB9ANPC1SMN1; SMN2ESRRGMAPT | |
| SCHEMBL711755 | 0.96 | RAB9A (0.81) | RAB9ANPC1SMN1; SMN2ESRRGMAPT | |
| SCHEMBL2830919 | 0.96 | RAB9A (0.81) | RAB9ANPC1SMN1; SMN2ESRRGMAPT | |
| SCHEMBL20115425 | 0.93 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2ESRRGMAPT | |
| SCHEMBL21292680 | 0.93 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2ESRRGMAPT | |
| SCHEMBL1563349 | 0.93 | RAB9A (0.77) | RAB9ANPC1SMN1; SMN2ESRRGMAPT | |
| SCHEMBL6634765 | 0.93 | RAB9A (0.77) | RAB9ANPC1SMN1; SMN2ESRRGMAPT | |
| SCHEMBL1563347 | 0.93 | RAB9A (0.77) | RAB9ANPC1SMN1; SMN2ESRRGMAPT | |
| SCHEMBL13568982 | 0.92 | RAB9A (0.87) | RAB9ANPC1SMN1; SMN2ESRRGMAPT | |
| SCHEMBL13475702 | 0.92 | RAB9A (0.74) | RAB9ANPC1SMN1; SMN2ESRRGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2862883-B1 | METHOD FOR PRODUCING NUCLEATOR MASTERBATCH | ADEKA CORP (JP) | 2019-09-25 | — | — | EP | disclosed |
| US-20180161755-A1 | Metal-Organic Frameworks (MOFs), Method For Their Preparation And Their Application | UNIWERSYTET JAGIELLONSKI (PL) | 2018-06-14 | — | — | US | disclosed |
| US-9243127-B2 | Method for producing nucleator masterbatch | ADEKA CORPORATION (JP) | 2016-01-26 | — | — | US | disclosed |
| US-20150152248-A1 | METHOD FOR PRODUCING NUCLEATOR MASTERBATCH | ADEKA CORPORATION (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2862883-A1 | METHOD FOR PRODUCING NUCLEATOR MASTERBATCH | Adeka Corporation (JP) | 2015-04-22 | — | — | EP | disclosed |
| US-8288462-B2 | Polyolefin resin composition | ADEKA CORPORATION (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8183236-B2 | Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| US-20110218279-A1 | POLYOLEFIN RESIN COMPOSITION | ADEKA CORPORATION (JP) | 2011-09-08 | — | — | US | disclosed |
| US-20090088420-A1 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088420-A1 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS | TYMP, IMPDH1, SAMHD1 | RAB9A 3114/4885NPC1 777/4885SMN1; SMN2 3619/4885 |
| US-20180161755-A1 | Metal-Organic Frameworks (MOFs), Method For Their Preparation And Their Application | DCX, MDH2, PDHA2 | RAB9A 3864/4885NPC1 1997/4885SMN1; SMN2 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.